Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

	Gene summary
	Malignant transformation analysis
	Malignant transformation related pathway analysis
	Cell-cell communication analysis
	Single-cell gene regulatory network inference analysis
	Somatic mutation of malignant transformation related genes
	Related drugs of malignant transformation related genes

Gene: CELSR1

Gene summary for CELSR1

Gene summary.

Gene information	Species	Human
	Gene symbol	CELSR1
	Gene ID	9620
	Gene name	cadherin EGF LAG seven-pass G-type receptor 1
	Gene Alias	ADGRC1
	Cytomap	22q13.31
	Gene Type	protein-coding
	GO ID	GO:0001736
	UniProtAcc	Q9NYQ6

Top

Malignant transformation analysis

Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells

Malignant transformation involving gene list.

Entrez ID	Symbol	Replicates	Species	Organ	Tissue	Adj P-value	Log2FC	Malignancy
9620	CELSR1	GSM4909293	Human	Breast	IDC	2.75e-04	1.51e-01	0.1581
9620	CELSR1	GSM4909306	Human	Breast	IDC	6.31e-06	1.88e-01	0.1564
9620	CELSR1	GSM4909307	Human	Breast	IDC	6.87e-07	2.37e-01	0.1569
9620	CELSR1	GSM4909308	Human	Breast	IDC	2.12e-07	2.24e-01	0.158
9620	CELSR1	GSM4909317	Human	Breast	IDC	9.13e-05	1.59e-01	0.1355
9620	CELSR1	M5	Human	Breast	IDC	2.00e-02	3.32e-01	0.1598
9620	CELSR1	NCCBC2	Human	Breast	DCIS	2.73e-03	5.40e-01	0.1554
9620	CELSR1	P3	Human	Breast	IDC	2.53e-06	5.17e-01	0.1542
9620	CELSR1	DCIS2	Human	Breast	DCIS	6.56e-05	1.61e-02	0.0085
9620	CELSR1	CA_HPV_1	Human	Cervix	CC	1.81e-04	-1.12e-01	0.0264
9620	CELSR1	CCI_1	Human	Cervix	CC	2.36e-20	1.57e+00	0.528
9620	CELSR1	CCI_2	Human	Cervix	CC	2.47e-03	4.05e-01	0.5249
9620	CELSR1	CCI_3	Human	Cervix	CC	1.66e-21	8.72e-01	0.516
9620	CELSR1	sample3	Human	Cervix	CC	2.83e-03	1.91e-01	0.1387
9620	CELSR1	AEH-subject1	Human	Endometrium	AEH	4.66e-09	3.57e-01	-0.3059
9620	CELSR1	AEH-subject3	Human	Endometrium	AEH	7.57e-08	3.66e-01	-0.2576
9620	CELSR1	AEH-subject5	Human	Endometrium	AEH	1.78e-21	6.42e-01	-0.2953
9620	CELSR1	EEC-subject2	Human	Endometrium	EEC	6.75e-13	4.51e-01	-0.2607
9620	CELSR1	EEC-subject4	Human	Endometrium	EEC	1.57e-02	2.78e-01	-0.2571
9620	CELSR1	EEC-subject5	Human	Endometrium	EEC	1.24e-05	2.99e-01	-0.249

Page: 1 2 3 4 5 6 7

Transcriptomic changes along malignancy continuum.

Tissue	Expression Dynamics	Abbreviation
Breast		IDC: Invasive ductal carcinoma
		DCIS: Ductal carcinoma in situ
		Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers
Cervix		CC: Cervix cancer
		HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions
		N_HPV: HPV-infected normal cervix
Endometrium		AEH: Atypical endometrial hyperplasia
		EEC: Endometrioid Cancer
Esophagus		ESCC: Esophageal squamous cell carcinoma
		HGIN: High-grade intraepithelial neoplasias
		LGIN: Low-grade intraepithelial neoplasias
Lung		AAH: Atypical adenomatous hyperplasia
		AIS: Adenocarcinoma in situ
		IAC: Invasive lung adenocarcinoma
		MIA: Minimally invasive adenocarcinoma
Oral Cavity		EOLP: Erosive Oral lichen planus
		LP: leukoplakia
		NEOLP: Non-erosive oral lichen planus
		OSCC: Oral squamous cell carcinoma
Skin		AK: Actinic keratosis
		cSCC: Cutaneous squamous cell carcinoma
		SCCIS:squamous cell carcinoma in situ

∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer

Figure of enriched GO biological processes.

Tissue	Disease Stage	Enriched GO biological Processes
Colorectum	AD
Colorectum	SER
Colorectum	MSS
Colorectum	MSI-H
Colorectum	FAP

∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).

Page: 1 2 3 4 5 6 7 8 9

Enriched GO biological processes.

GO ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	Count
GO:006054112	Endometrium	EEC	respiratory system development	36/2168	203/18723	6.02e-03	3.57e-02	36
GO:003032414	Endometrium	EEC	lung development	32/2168	177/18723	6.93e-03	3.98e-02	32
GO:20000273	Endometrium	EEC	regulation of animal organ morphogenesis	24/2168	125/18723	8.60e-03	4.70e-02	24
GO:003297027	Esophagus	HGIN	regulation of actin filament-based process	77/2587	397/18723	1.14e-03	1.39e-02	77
GO:001605516	Esophagus	HGIN	Wnt signaling pathway	83/2587	444/18723	2.27e-03	2.33e-02	83
GO:003295627	Esophagus	HGIN	regulation of actin cytoskeleton organization	69/2587	358/18723	2.35e-03	2.39e-02	69
GO:019873816	Esophagus	HGIN	cell-cell signaling by wnt	83/2587	446/18723	2.58e-03	2.55e-02	83
GO:00018438	Esophagus	HGIN	neural tube closure	22/2587	88/18723	3.57e-03	3.27e-02	22
GO:00018389	Esophagus	HGIN	embryonic epithelial tube formation	28/2587	121/18723	3.72e-03	3.39e-02	28
GO:00140209	Esophagus	HGIN	primary neural tube formation	23/2587	94/18723	3.92e-03	3.54e-02	23
GO:00606067	Esophagus	HGIN	tube closure	22/2587	89/18723	4.14e-03	3.70e-02	22
GO:000184114	Esophagus	HGIN	neural tube formation	24/2587	102/18723	5.54e-03	4.52e-02	24
GO:001605517	Esophagus	ESCC	Wnt signaling pathway	268/8552	444/18723	2.32e-10	6.58e-09	268
GO:019873817	Esophagus	ESCC	cell-cell signaling by wnt	269/8552	446/18723	2.41e-10	6.79e-09	269
GO:000184115	Esophagus	ESCC	neural tube formation	75/8552	102/18723	9.68e-09	1.95e-07	75
GO:000184314	Esophagus	ESCC	neural tube closure	66/8552	88/18723	1.98e-08	3.82e-07	66
GO:001402014	Esophagus	ESCC	primary neural tube formation	69/8552	94/18723	4.22e-08	7.76e-07	69
GO:006060614	Esophagus	ESCC	tube closure	66/8552	89/18723	4.24e-08	7.76e-07	66
GO:000726510	Esophagus	ESCC	Ras protein signal transduction	201/8552	337/18723	1.44e-07	2.30e-06	201
GO:00219159	Esophagus	ESCC	neural tube development	101/8552	152/18723	1.78e-07	2.79e-06	101

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Enriched KEGG pathways.

Pathway ID

Tissue

Disease Stage

Description

Gene Ratio

Bg Ratio

pvalue

p.adjust

qvalue

Count

Page: 1

Top

Cell-cell communication analysis

Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states

Ligand

Receptor

LRpair

Pathway

Tissue

Disease Stage

Page: 1

Top

Single-cell gene regulatory network inference analysis

Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states

Cell Type

Tissue

Disease Stage

Target Gene

RSS

Regulon Activity

∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.

Page: 1

Top

Somatic mutation of malignant transformation related genes

Annotation of somatic variants for genes involved in malignant transformation

Hugo Symbol

Variant Class

Variant Classification

dbSNP RS

HGVSc

HGVSp

HGVSp Short

SWISSPROT

BIOTYPE

SIFT

PolyPhen

Tumor Sample Barcode

Tissue

Histology

Sex

Age

Stage

Therapy Types

Drugs

Outcome

CELSR1

SNV

Missense_Mutation

rs73888514

c.4171N>A

p.Glu1391Lys

p.E1391K

Q9NYQ6

protein_coding

tolerated(0.08)

benign(0.425)

TCGA-3C-AALI-01

Breast

breast invasive carcinoma

Female

<65

I/II

Unspecific

Poly E

Complete Response

CELSR1

SNV

Missense_Mutation

novel

c.8630G>A

p.Ser2877Asn

p.S2877N

Q9NYQ6

protein_coding

tolerated(0.32)

benign(0.05)

TCGA-A2-A4RW-01

Breast

breast invasive carcinoma

Female

<65

III/IV

Unknown

CELSR1

SNV

Missense_Mutation

c.6920C>T

p.Thr2307Ile

p.T2307I

Q9NYQ6

protein_coding

tolerated(0.42)

benign(0.216)

TCGA-A8-A08R-01

Breast

breast invasive carcinoma

Female

<65

I/II

Unknown

CELSR1

SNV

Missense_Mutation

rs146465806

c.8269N>A

p.Glu2757Lys

p.E2757K

Q9NYQ6

protein_coding

tolerated(0.09)

possibly_damaging(0.636)

TCGA-AC-A8OQ-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

CELSR1

SNV

Missense_Mutation

rs143915949

c.8410N>A

p.Asp2804Asn

p.D2804N

Q9NYQ6

protein_coding

deleterious(0.01)

possibly_damaging(0.871)

TCGA-C8-A27B-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

5-fluorouracil

CELSR1

SNV

Missense_Mutation

rs775423517

c.8191G>A

p.Ala2731Thr

p.A2731T

Q9NYQ6

protein_coding

tolerated(0.11)

benign(0.157)

TCGA-D8-A1XK-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

doxorubicine+cyclophosphamide

CELSR1

SNV

Missense_Mutation

novel

c.3998N>G

p.Ser1333Cys

p.S1333C

Q9NYQ6

protein_coding

deleterious(0)

probably_damaging(0.993)

TCGA-E9-A3QA-01

Breast

breast invasive carcinoma

Female

<65

I/II

Unknown

CELSR1

SNV

Missense_Mutation

c.860T>C

p.Leu287Pro

p.L287P

Q9NYQ6

protein_coding

deleterious(0.02)

probably_damaging(0.995)

TCGA-EW-A1P0-01

Breast

breast invasive carcinoma

Female

<65

I/II

Hormone Therapy

arimidex

CELSR1

insertion

Nonsense_Mutation

novel

c.5926_5927insTCGTGTCTCCAGAAATGCACACGCGTTCTCAGTGCAGACTCTAGGGA

p.Pro1976LeufsTer15

p.P1976Lfs*15

Q9NYQ6

protein_coding

TCGA-BH-A0HF-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Hormone Therapy

arimidex

CELSR1

insertion

Frame_Shift_Ins

novel

c.5313_5314insC

p.Gly1772ArgfsTer14

p.G1772Rfs*14

Q9NYQ6

protein_coding

TCGA-C8-A1HK-01

Breast

breast invasive carcinoma

Female

<65

I/II

Unknown

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31

Top

Related drugs of malignant transformation related genes

Identification of chemicals and drugs interact with genes involved in malignant transfromation

(DGIdb 4.0)

Entrez ID

Symbol

Category

Interaction Types

Drug Claim Name

Drug Name

PMIDs

Page: 1